A Probiotic Strain Blunted Alcohol-Linked Liver Injury in Mice

Researchers in South Korea have reported that a probiotic strain, Lacticaseibacillus paracasei WiKim0110, reduced several signs of alcohol-related gut and liver injury in mice, adding new evidence to a growing area of research on the gut-liver axis and the biological damage linked to drinking.

The study was published on Aug. 23 in Scientific Reports by scientists at the World Institute of Kimchi, Chung-Ang University, Dongshin University and Korea University. It examined whether the bacterial strain could blunt harm caused by alcohol feeding in mice, a model often used to study early mechanisms involved in alcoholic liver disease.

Alcohol is known to disrupt the gut-liver axis, the close biological link between the intestine and the liver. When the intestinal barrier is weakened, bacterial products can move more easily from the gut into circulation and reach the liver, where they can fuel inflammation and metabolic stress. That process has become an important target for researchers trying to understand how heavy alcohol use damages the body.

In the new study, mice that were fed alcohol showed lower body weight, higher liver weight and increased blood levels of alanine aminotransferase and aspartate aminotransferase, two enzymes commonly used as markers of liver injury. According to the researchers, supplementation with WiKim0110 significantly improved those measures.

The team also found changes in the large intestine that suggested stronger barrier function in the supplemented mice. Alcohol exposure had impaired intestinal defenses, but the probiotic increased the expression of mucin-related genes known as Muc2 and Muc3a, as well as Atoh1, a factor involved in goblet-cell differentiation. Goblet cells help produce the mucus layer that protects the intestinal lining.

At the same time, the strain reduced expression of Tlr4 and Cd14, two markers involved in sensing lipopolysaccharide, or LPS, a bacterial component that can trigger innate immune responses. The researchers said that pattern points to weaker LPS-related immune signaling, which is relevant because LPS leakage from the gut has long been implicated in alcohol-related liver inflammation.

One of the stronger intestinal signals in the paper involved Reg3g, a gene tied to antimicrobial defense in the gut lining. The authors said WiKim0110 markedly increased Reg3g expression, suggesting that the bacterium may help reinforce the epithelial barrier and support the intestine’s ability to keep microbes at a distance.

The microbiome data also showed a clear alcohol effect and a partial reversal with supplementation. Alcohol-fed mice had lower alpha diversity, a common measure of microbial richness and balance, and a rise in Escherichia-Shigella, a group often associated with dysbiosis and inflammation. In the mice that received WiKim0110, the researchers found enrichment of taxa including Bacteroides, Akkermansia and Romboutsia, changes they said were consistent with at least a partial restoration of the alcohol-disrupted gut ecosystem.

In the liver, the probiotic was associated with lower expression of inflammatory and fat-production genes, including Il1b, Fasn and Acaca. It also increased the expression of antioxidant-related genes Sod1 and Nfe2l2. Together, those shifts suggested less inflammatory stress and a stronger antioxidant response in the supplemented animals.

The work does not show that probiotics prevent alcohol-related disease in people, and the authors did not present the findings as a clinical solution. The study was done in mice, and results from animal models often fail to translate directly to humans. It also focused on one bacterial strain, which means the findings cannot be assumed to apply to probiotics more broadly.

Even so, the paper adds to a field that is drawing attention from gastroenterology, microbiology and nutrition researchers as well as public health specialists. Alcohol-related liver disease remains a major cause of illness worldwide, and scientists have been looking for ways to interrupt the chain of events that links alcohol intake to intestinal permeability, microbiome imbalance and liver inflammation.

The strain tested in the study was described as a gut-derived lactic acid bacterium. The paper’s ethics statement said the fecal sample used in the research came from a healthy infant donor with parental consent, and that the study protocol was approved by an institutional review board at Mokpo Korean Medicine Hospital, Dongshin University. The authors said they had no competing interests.

The research was supported by the World Institute of Kimchi, the Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry, and Fisheries through the Agricultural Microbiome R&D Program backed by the Ministry of Agriculture, Food and Rural Affairs, and the Korea Innovation Foundation through a project funded by the Ministry of Science and ICT.

For the beverage sector, the findings may have potential relevance because they add to scientific evidence on how alcohol can damage the gut-liver axis and how that damage might be modulated. That could inform public health discussions around drinking and may also be watched by companies involved in functional beverages, fermentation and ingredient development. But the study does not suggest that adding probiotics to a product would offset the risks of alcohol consumption, and it offers no basis for health claims in consumers without human trials.

The next step for the field is likely to be clinical testing. Researchers will need to establish whether WiKim0110 can survive and function in people in the same way it did in mice, determine safe and effective dosing, and show measurable benefits in controlled studies involving drinkers or patients with alcohol-related liver conditions. They will also need to clarify how much of the apparent effect came from microbiome shifts, immune signaling, mucus production or direct metabolic changes in the liver.